Table 2 Primary and secondary overall effectiveness end points by regions (ITT population)

From: Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy

Parameter Overall, N=43 791 Europe, n=22 073 India, n=10 692 Middle East, n=4779 Latin America, n=3846 East Asia, n=2401
Primary effectiveness end point a
 Success rate 23 533 (53.7) 10 642 (48.2) 6738 (63.0) 3301 (69.1) 2229 (58.0) 623 (26.0)
 Non-evaluable 11 395 (26.0) 5877 (26.6) 2442 (22.8) 858 (18.0) 1048 (27.3) 1170 (48.7)
 OR (95% CI) 1 0.8 (0.81, 0.87) 1.5 (1.47, 1.59) 2.0 (1.90, 2.12) 1.2 (1.17, 1.31) 0.3 (0.29, 0.34)
Secondary effectiveness end point b
 Success rate 11 040 (30.8) 5498 (32.7) 2002 (20.4) 1922 (43.0) 1306 (42.0) 312 (19.0)
 Non-evaluable 6897 (19.2) 3754 (22.3) 1158 (11.8) 631 (14.1) 608 (19.6) 746 (45.5)
 OR (95% CI) 1 1.1 (1.07, 1.16) 0.6 (0.56, 0.62) 1.7 (1.63, 1.82) 1.7 (1.56, 1.77) 0.5 (0.49, 0.59)
  1. Abbreviations: CI, confidence interval; ITT, intention-to-treat; OR, odds ratio.
  2. aThe proportion of patients in all the five regions achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without any tolerability issues, such as peripheral edema, hypoglycemia, discontinuation owing to a gastrointestinal event or a weight gain of 5% at 12 months.
  3. bIn patients with a baseline HbA1c of 7.0%, achievement of the target HbA1c of <7.0% at the 12-month end point, without a weight gain of 3% at 12 months or hypoglycemic event.